|
1
|
Orth M, Lauber K, Niyazi M, Friedl AA, Li
M, Maihöfer C, Schüttrumpf L, Ernst A, Niemöller OM and Belka C:
Current concepts in clinical radiation oncology. Radiat Environ
Biophys. 53:1–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hoskin PJ and Bhattacharya IS: Protons and
more: State of the art in radiotherapy. Clin Med (Lond). 14 Suppl
6:s61–s65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xie G, Gu D, Zhang L, Chen S and Wu D: A
rapid and systemic complete response to stereotactic body radiation
therapy and pembrolizumab in a patient with metastatic renal cell
carcinoma. Cancer Biol Ther. 18:547–551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharabi A, Kim SS, Kato S, Sanders PD,
Patel SP, Sanghvi P, Weihe E and Kurzrock R: Exceptional response
to nivolumab and stereotactic body radiation therapy (SBRT) in
neuroendocrine cervical carcinoma with high tumor mutational
burden: Management considerations from the center for personalized
cancer therapy at UC San diego moores cancer center. Oncologist.
22:631–637. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abuodeh Y, Venkat P and Kim S: Systematic
review of case reports on the abscopal effect. Cur Probl Cancer.
40:25–37. 2016. View Article : Google Scholar
|
|
6
|
Garnett C, Palena C, Chakarborty M, Tsang
KY, Schlom J and Hodge JW: Sublethal irradiation of human tumor
cells modulates phenotype resulting in enhanced killing by
cytotoxic T lymphocytes. Cancer Res. 64:7985–7994. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz
DP, Goldstein J, Nelson PS, Desprez PY and Campisi J:
Senescence-associated secretory phenotypes reveal
cell-nonautonomous functions of oncogenic RAS and the p53 tumor
suppressor. PLoS Biol. 6:2853–2868. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kojima T, Hara H, Yamaguchi K, Hironaka S,
Iwasa S, Kato K, Iwasa S, Kato K, Tsushima T, Yasui T, et al: Phase
II study of nivolumab (ONO-4538/BMS-936558) in patients with
esophageal cancer: Preliminary report of overall survival. J Clin
Oncol. 34 Suppl 4:TPS175. 2016. View Article : Google Scholar
|
|
10
|
Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H,
Yuan S, Koshiji M, Csiki I and Bennouna J: Pembrolizumab (MK-3475)
for patients (pts) with advanced esophageal carcinoma: Preliminary
results from KEYNOTE-028. J Clin Oncol. 33 15-Suppl:S40102015.
|
|
11
|
Mole RH: Whole body irradiation;
radiobiology or medicine? Br J Radiol. 26:234–241. 1953. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Polistena A, Johnson LB, Ohiami-Masseron
S, Wittgren L, Bäck S, Thornberg C, Gadaleanu V, Adawi D and
Jeppsson B: Local radiotherapy of exposed murine small bowel:
Apoptosis and inflammation. BMC Surg. 8:12008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Golden EB, Demaria S, Schiff PB, Chachoua
A and Formenti SC: An abscopal response to radiation and ipilimumab
in a patient with metastatic non-small cell lung cancer. Cancer
Immunol Res. 1:365–372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grimaldi AM, Simeone E, Giannarelli D,
Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F,
Petrillo A, Curvietto M, et al: Abscopal effects of radiotherapy on
advanced melanoma patients who progressed after ipilimumab
immunotherapy. Oncoimmunology. 3:e287802014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gomes Ribeiro J, Schmerling RA, Haddad CK,
Racy DJ, Ferrigno R, Gil E, Zanuncio P and Buzaid AC: Analysis of
the abscopal effect with anti-PD1 therapy in patients with
metastatic solid tumors. J Immunother. 39:367–372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Slovin SF, Higano CS, Hamid O, Tejwani S,
Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB
and Beer TM: Ipilimumab alone or in combination with radiotherapy
in metastatic castration-resistant prostate cancer: Results from an
open-label, multicenter phase I/II study. Ann Oncol. 24:1813–1821.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marconi R, Strolin S, Bossi G and Strigari
L: A meta-analysis of the abscopal effect in preclinical models: Is
the biologically effective dose a relevant physical trigger? PLoS
One. 12:e01715592017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cabel L, Riva F, Servois V, Livartowski A,
Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, et
al: Circulating tumor DNA changes for early monitoring of anti-PD1
immunotherapy: A proof-of-concept study. Ann Oncol. 28:1996–2001.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guibert N, Mazieres J, Delaunay M,
Casanova A, Farella M, Keller L, Favre G and Pradines A: Monitoring
of KRAS-mutated ctDNA to discriminate pseudo-progression from true
progression during anti-PD-1 treatment of lung adenocarcinoma.
Oncotarget. 8:38056–38060. 2017. View Article : Google Scholar : PubMed/NCBI
|
